BioSpace News Archive

Extendicare Inc. (“Extendicare” or the “Company”) (TSX: EXE) today announced the results of matters voted on at its annual shareholders’ meeting held on May 28, 2020 (the “Meeting”), which included the election as directors of the Company of all of the nominees listed in its management information and proxy circular dated April 16, 2020 (the “Information Circular”).

Zentalis Pharmaceuticals (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on developing clinically differentiated, novel small molecule therapeutics that target fundamental pathways of cancers, today announced that Anthony Sun, MD, Chairman and Chief Executive Officer of Zentalis, will participate in a fireside chat at the Jefferies Virtual Healthcare Conference on Thursday, June 4, 2020 at 1:30 p.m. ET.

Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical stage biotechnology company focused on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases, today announced the expansion of its Sponsored Research Agreement (SRA) with the University of Pennsylvania (Penn). The

Syapse, today announced $30 million in new equity funding to accelerate the creation and use of real-world evidence in oncology. The financing was led by Revelation Alpine, LLC, with participation from existing investors including Amgen Ventures, Ascension Ventures, Intermountain Ventures, Merck Global Health Innovation Fund, Roche Finance Ltd, Safeguard Scientifics and Social Capital. Revelation Alpine’s Managing Partner Zack Scott, MD will join

IntelGenx Technologies Corp. (TSX-V:IGX) (OTCQB:IGXT) (“ IntelGenx ” or the “ Corporation ”) today announced that it intends to issue shares of common stock (“ Common Shares ”) of the Corporation in payment of the outstanding $7,577,000 aggregate principal amount of the Corporation’s 8.00% convertible unsecured subordinated debentures due June 30, 2020 (the “ Debentures ”). Under the terms of the trust indenture governing the Debentures

Delivering on a commitment the company made in April, CVS Health will open additional COVID-19 test sites at select CVS Pharmacy drive-thru locations on Friday, May 29 to establish a total of 1,000 sites across more than 30 states and Washington, DC.

scPharmaceuticals Inc. (Nasdaq:SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs, today announced that John Tucker, chief executive officer, will present at the following investor conferences in June: Jefferies Virtual Healthcare Conference Presentation: Thurs

VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, today announced the formation of a Commercial Advisory Board consisting of leading experts in public health policy, epidemiology, and vaccine development. The Commercial Advisory Board will work closely with VBI’s management team on pre-commercialization and comm

Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage therapeutics company focused on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose and throat diseases, today announced that Maria Palasis, Ph.D., Lyra’s President and Chief Executive Officer, will present at the Jefferies Virtual Global Healthcare Conference on Thursday, June

The U.S. Food and Drug Administration reviewed the Company’s request for Fast Track designation and concluded that investigation of onvansertib, in combination with FOLFIRI/bevacizumab, for second-line treatment of patients with KRAS-mutated metastatic colorectal cancer meets the criteria for a Fast Track development program